Adaptimmune Therapeutics PLC (ADAP)
0.6616
+0.02
(+3.93%)
USD |
NASDAQ |
Nov 22, 16:00
0.66
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Cash from Operations (Quarterly): -54.45M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -54.45M |
| June 30, 2024 | 47.40M |
| March 31, 2024 | -31.95M |
| December 31, 2023 | -14.68M |
| September 30, 2023 | -45.16M |
| June 30, 2023 | -43.76M |
| March 31, 2023 | -37.28M |
| December 31, 2022 | 2.042M |
| September 30, 2022 | -48.16M |
| June 30, 2022 | -41.25M |
| March 31, 2022 | -54.40M |
| December 31, 2021 | 133.93M |
| September 30, 2021 | -45.20M |
| June 30, 2021 | -31.46M |
| March 31, 2021 | -46.54M |
| December 31, 2020 | -29.22M |
| September 30, 2020 | -16.32M |
| June 30, 2020 | -24.92M |
| March 31, 2020 | 16.86M |
| Date | Value |
|---|---|
| December 31, 2019 | -12.53M |
| September 30, 2019 | -29.61M |
| June 30, 2019 | -34.17M |
| March 31, 2019 | -36.20M |
| December 31, 2018 | -31.68M |
| September 30, 2018 | 9.939M |
| June 30, 2018 | -35.36M |
| March 31, 2018 | -47.28M |
| December 31, 2017 | -21.36M |
| September 30, 2017 | 13.49M |
| June 30, 2017 | -18.01M |
| March 31, 2017 | -28.44M |
| December 31, 2016 | 2.37M |
| September 30, 2016 | -15.37M |
| June 30, 2016 | -16.49M |
| March 31, 2016 | -18.68M |
| September 30, 2015 | -0.2667M |
| December 31, 2014 | -2.051M |
| September 30, 2014 | -13.10M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-54.45M
Minimum
Sep 2024
133.93M
Maximum
Dec 2021
-18.85M
Average
-31.70M
Median
Cash from Operations (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -1.446M |
| Autolus Therapeutics PLC | -76.74M |
| TC BioPharm (Holdings) PLC | -3.055M |
| Verona Pharma PLC | -62.66M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -66.02M |
| Cash from Financing (Quarterly) | 25.00M |
| Free Cash Flow | -56.05M |
| Free Cash Flow Per Share (Quarterly) | -0.2146 |
| Free Cash Flow to Equity (Quarterly) | -79.80M |
| Free Cash Flow to Firm (Quarterly) | -54.89M |
| Free Cash Flow Yield | -34.41% |